Key facts
- This page summarizes Robert Lorne Hopfner's Form 4 filing for Inozyme Pharma, Inc. (INZY).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Jul 2025, 18:59.
Robert Lorne Hopfner - 01 Jul 2025 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)
- Reporting relationship
- Director
- Issuer ticker
- INZY
- Reported as of
- 01 Jul 2025
- Net transaction value
- -$17,979,404
- SEC form
- 4
- Accepted by SEC
- 03 Jul 2025, 18:59:42 UTC
- Prior SEC filing
- 15 May 2025
- Next SEC filing
- 05 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sanjay Subramanian, as attorney-in-fact for Robert Hopfner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Lorne Hopfner filed Form 4 for Inozyme Pharma, Inc. (INZY) on 03 Jul 2025.
Change
- Previous filing in this sequence was filed on 15 May 2025.
- Current net transaction value: -$17,979,404.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001551966
Primary reporting owner
Hopfner Robert Lorne
- Relationship
- Director
- Address
- C/O INOZYME PHARMA, INC., 321 SUMMER STREET SUITE 400, BOSTON
- Signature
- /s/ Sanjay Subramanian, as attorney-in-fact for Robert Hopfner
- Signature date
- 03 Jul 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INZY
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- $11,692,440
- Shares
- -2,923,110
- Change %
- -100%
- Price
- $4.00
- Shares after
- 0
- Date
- 01 Jul 2025
- Ownership
- By Pivotal
- Footnotes
- F1, F2, F3, F4, F5
INZY
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- $6,286,964
- Shares
- -1,571,741
- Change %
- -100%
- Price
- $4.00
- Shares after
- 0
- Date
- 01 Jul 2025
- Ownership
- By Pivotal
- Footnotes
- F1, F2, F4, F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Robert Lorne Hopfner is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 6 footnotes
Footnote F1
This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger").
Footnote F2
Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.
Footnote F3
Held directly by Pivotal bioVenture Partners Fund I, L.P.
Footnote F4
The general partner of Pivotal bioVenture Partners Fund I, L.P and Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal") is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").
Footnote F5
Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such persons and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.
Footnote F6
Held directly by Pivotal bioVenture Partners Fund II, L.P.